SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Acumen to Stop Sabirnetug Development After Phase 2 Trial Failure

Acumen Pharmaceuticals said it plans to stop development of sabirnetug following a failed Phase 2 trial.

ABOS

Related stories